文献速递抗栓抗凝管理药物不良反应与药物警戒

亚洲房颤抗凝患者出血风险评分比较验证:COOL-AF注册研究

Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
PubMed 文献 · Br J Clin Pharmacol · 2023-04-04

基于COOL-AF全国注册研究中2568例口服抗凝的亚洲房颤患者,比较HAS-BLED、GARFIELD-AF与ORBIT评分对主要出血的预测效能。四种模型的C统计量相近(0.64–0.69),改良HAS-BLED的NRI优于HAS-BLED与ORBIT,但与GARFIELD-AF相似;ORBIT较HAS-BLED无优势。

要点

  • 四种评分对主要出血的区分度相近,C统计量0.64–0.69。
  • 改良HAS-BLED的NRI优于HAS-BLED(26.9%)和ORBIT(31.9%),与GARFIELD-AF相似。
  • ORBIT较HAS-BLED无预测优势,在直接口服抗凝药使用者中亦然。

核心结论

  • 在COOL-AF注册研究的亚洲抗凝房颤患者中,GARFIELD-AF、HAS-BLED、改良HAS-BLED与ORBIT评分的出血预测临床效用相似。
  • ORBIT较HAS-BLED在出血风险预测上无优势,即使在直接口服抗凝药使用者中亦如此。

研究设计与样本

  • COOL-AF注册研究中基线接受口服抗凝药的房颤患者被纳入分析,共2568例。
  • 将HAS-BLED、GARFIELD-AF与ORBIT评分变量拟合Cox模型预测主要出血,并探索加入性别与体重的改良HAS-BLED。
  • 采用区分度、校准、净重分类指数(NRI)与决策曲线分析比较三种模型的表现。

主要发现

  • 注册研究3402例患者中,2568例基线接受口服抗凝药,其中91.1%使用华法林。
  • 主要出血发生率为2.11/100人年。
  • GARFIELD-AF、HAS-BLED、改良HAS-BLED与ORBIT评分的C统计量分别为0.65(95%CI 0.63-0.67)、0.66(95%CI 0.64-0.68)、0.69(95%CI 0.67-0.71)与0.64(95%CI 0.62-0.66)。
  • HAS-BLED与GARFIELD-AF评分的十分位分组中预测与 observed 出血一致性良好,改良HAS-BLED与ORBIT在最后一个十分位高估风险。
  • 改良HAS-BLED的NRI优于HAS-BLED(26.9%,95%CI 9.7%-42.2%)与ORBIT(31.9%,95%CI 9.0-53.6%),与GARFIELD-AF相似。

临床怎么用

  • 在亚洲口服抗凝房颤患者中,HAS-BLED、GARFIELD-AF、改良HAS-BLED与ORBIT均可用于出血风险预测,效能相近。
  • ORBIT并不优于HAS-BLED,选择评分时可优先考虑HAS-BLED或其改良版本。

局限性

  • 研究对象以华法林使用者为主(91.1%),直接口服抗凝药使用者占比较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Comparative data between the HAS-BLED, GARFIELD-AF and ORBIT score are limited in anticoagulated Asian patients with atrial fibrillation (AF). We compared the performance of the 3 scores in a nationwide registry. METHODS: AF patients treated with oral anticoagulants in the COOL-AF registry were studied. We fitted the variables of the HAS-BLED, GARFIELD-AF and ORBIT score to major bleeding in Cox model. We explored a modified HAS-BLED by addition of sex and body weight. Discrimination, calibration, net reclassification index (NRI) and decision curve analysis were used to compare the performance of the 3 models. RESULTS: Of 3402 patients in the registry, 2568 patients who received oral anticoagulant at baseline were studied. Majority of patients (91.1%) received warfarin. The rate of major bleeding was 2.11 per 100 person-years. The C-statistics of the GARFIELD-AF, HAS-BLED, modified HAS-BLED and ORBIT score were 0.65 (95% confidence interval [CI] 0.63-0.67), 0.66 (95%CI 0.64-0.68), 0.69 (95%CI 0.67-0.71) and 0.64 (95%CI 0.62-0.66) respectively. There was good agreement between predicted and observed bleeding in the deciles of HAS-BLED and GARFIELD-AF scores, while the modified HAS-BLED score and ORBIT score overestimated the risk in the last decile. The modified HAS-BLED score had superior NRI than the HAS-BLED score (26.9%, 95%CI 9.7%-42.2%) and the ORBIT score (31.9%, 95%CI 9.0-53.6%). The NRI between the modified HAS-BLED and GARFIELD-AF score was similar. The net benefit curve of the 4 models were overlapping among different thresholds. CONCLUSIONS: The clinical utility for bleeding prediction of GARFIELD-AF, HAS-BLED, modified HAS-BLED and ORBIT scores were similar in anticoagulated Asian patients with AF participating in the COOL-AF registry. We found no advantage of the ORBIT over HAS-BLED score for bleeding risk prediction, even in direct oral anticoagulant users.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chichareon P, Winijkul A, Lip GYH, et al. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry. Br J Clin Pharmacol. 2023. PMID: 36942465. doi:10.1111/bcp.15716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。